Business Context and Reporting Period
Priveterra Acquisition Corp. filed this Form 8-K on July 5, 2023, reporting actions taken at its July 3, 2023 special meeting regarding its proposed business combination with AEON Biopharma, Inc. Upon closing, Priveterra is expected to become “New AEON” and change its name to AEON Biopharma, Inc.
Key Financial Metrics and Capitalization
This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity results.
- Stockholders approved the issuance of up to 39,913,926 Class A common shares in connection with the business combination.
- Stockholders also approved the issuance of up to 14,564,286 Class A common shares related to concurrent financing arrangements.
- Public stockholders elected to redeem 1,681,348 Class A common shares for their pro rata share of the trust account. The filing does not provide the resulting dollar amount or final post-redemption cash balance.
Material Changes and Transaction Status
- The business combination agreement and related transactions were approved with 8,189,816 votes for and 239,010 against.
- The proposed charter and bylaws for New AEON were approved.
- Stockholders approved the election of Marc Forth, Jost Fischer, Eric Carter, Robert Palmisano, and Shelley Thunen as directors of New AEON, serving staggered terms.
- The New AEON 2023 Incentive Award Plan and 2023 Employee Stock Purchase Plan were approved.
- Approval was obtained to increase authorized common stock to 500,000,000 shares and authorized preferred stock to 1,000,000 shares, although these advisory charter proposals were non-binding.
Guidance, Outlook, Risks, and Unusual Items
The closing was expected to occur in July 2023, subject to satisfaction or waiver of the conditions in the business combination agreement. Redemption elections could be revoked before closing, so the final redemption amount and capitalization may change.
The filing contains forward-looking statements regarding the transaction and future performance. Identified risks include failure to complete the business combination, changes in redemption levels, financing and capitalization uncertainty, and other risks described in the company’s SEC filings, including the definitive proxy statement and related registration statement.
Important Facts for Investors to Verify
- Whether and when the business combination closed.
- The final number of shares redeemed and the resulting trust-account proceeds and cash balance.
- The final shares issued in the transaction and concurrent financing arrangements.
- The effective name, ticker symbols, capital structure, and Nasdaq listing status of the combined company.
- AEON Biopharma’s post-closing financial results, liquidity, debt, operating losses, and commercial or clinical outlook, none of which are provided in this 8-K.